Goethe University Frankfurt
Verified site
Frankfurt, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on patients with small-cell lung cancer that has returned after initial treatment and spread widely (relapsed extensive disease). The investigational drug being used is tarlatamab, a therapy given by intravenous infusion. If the cancer shows signs of growing again while on this drug, the protocol calls for a repeat course of standard chemotherapy drugs, specifically carboplatin and etoposide, also delivered by infusion.
The purpose of the study is to determine whether giving the standard chemotherapy again after progression on tarlatamab can control the disease. Participants will first receive the investigational drug; if their disease progresses, they will start a series of chemotherapy cycles with the two standard drugs. Each cycle consists of a short hospital visit for the infusion followed by a recovery period, and patients will be monitored for side effects such as immune reactions (known as CRS) and neurological symptoms (ICANS).
Patients will be followed for several months to assess how long the disease stays stable without worsening, a measure called progression-free survival, which reflects the time from the start of the chemotherapy repeat until the cancer grows again. Additional assessments include overall survival, the proportion of patients whose tumors shrink (response rate), and the safety of the treatment. Tumor changes are evaluated using standard imaging criteria referred to as RECIST, which provides a consistent way to measure tumor size and response.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
22 criteria
18 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Frankfurt, Germany
Munich, Germany
Cologne, Germany
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an investigational medicine called tarlatamab. It is given through a vein as a liquid and is designed to help the immune system recognize and attack small‑cell lung cancer cells. In this study, patients receive IMDYLLTRA while their disease is being monitored, and the drug’s effect on the cancer is evaluated.
is a chemotherapy drug that belongs to the platinum‑based class. It is given by infusion into a vein and works by damaging the DNA of cancer cells, which prevents them from growing and dividing. In this trial, carboplatin is used again (re‑challenge) to treat patients whose cancer has progressed while they were on IMDYLLTRA.
is another chemotherapy medication given through an intravenous infusion. It interferes with the ability of cancer cells to copy their DNA, leading to cell death. In the trial, etoposide is combined with carboplatin as a re‑challenge therapy for patients whose disease has gotten worse during treatment with IMDYLLTRA.
This drug is given as a powder that is mixed with liquid to create an intravenous infusion. It is still an experimental medicine and has orphan‑drug status while being studied in clinical trials. It is being tested for use in relapsed extensive‑stage small‑cell lung cancer. Tarlatamab works as a bispecific antibody that attaches to a protein called DLL3 on cancer cells and to CD3 on T‑cells, directing the immune cells to attack the tumor; it belongs to the class of bispecific T‑cell engager immunotherapies.
Carboplatin is supplied as a sterile solution for intravenous infusion. It is an approved, widely used chemotherapy drug that is listed in medical references. It is used to treat cancers such as small‑cell lung cancer, ovarian cancer, and others. The drug contains platinum, which binds to DNA and creates cross‑links that stop cancer cells from copying their genetic material; it is classified as a platinum‑based alkylating‑like chemotherapy agent.
Etoposide comes as a concentrate that is mixed with fluid for intravenous infusion. It is an established, approved anticancer medication found in standard treatment guidelines. It is used for small‑cell lung cancer, testicular cancer, and certain other tumors. The medicine blocks an enzyme called topoisomerase II, causing breaks in DNA that lead to cancer cell death; it belongs to the class of topoisomerase II inhibitor cytotoxic chemotherapy.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.